IgA Nephropathy: Modern Laboratory Diagnostics and Value of Renal Biopsy;IgA Nefropatie. Užití Moderních Laboratorních Metod a Biopsie Ledviny v Diagnostice

Vnitrni Lekarstvi

Volumn 49, Issue 11, 2003, Pages 869-873

  Matoušovic, Karel ^a   Martinek V ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Glycoproteins; IgA nephropathy; Immunoglobulin A; N acetylgalactosamine

Indexed keywords

FIBRONECTIN; GLYCOPROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; N ACETYLGALACTOSAMINE; N ACETYLGALACTOSAMINE ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; GLOMERULONEPHRITIS; HEMATURIA; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEPOSITION; IMMUNOPATHOLOGY; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LABORATORY TEST; PATHOPHYSIOLOGY;

EID: 0344014106     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Allen, A., Feehally, J.: IgA glycosylation in IgA nephropathy. Adv. Exp. Med. Biol., 2, 1998; 175-183
2. Coppo, R., Basolo, B., Martina, G. et al.: Circulation immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and Henoch-Scoenlein nephritis. Correlation with clinical and histologic signs of activity. Clin. Nephrol. 18, 1982; 5: 230-239
3. Czerkinski, C., Koopman, W. J., Jacsson, C. et al.: Circulating immune complexes and immunoglobuline A rheumatoid factor in patients with mesangial immunoglobuline A nephropathies. J. clin. Invest. 77, 1986; 6: 1931-1938
4. Donadio, J. V.: IgA nephropathy. N. Engl. J. Med. 347, 2002; 10: 738-748
5. Floege, J., Feehally, J.: IgA nephropathy. Recent development. J. Am. Soc. Nephrol. 11, 2000; 12: 2395-2403
6. Galla, J. H., Spotwood, M. F., Harrison, L. A. et al.: Urinary IgA in IgA nephropathy and Henoch-Schoenlein purpura. J. Clin. Immunology 5, 1985; 5: 298-306
7. Galili, U.: Abnormal expression of α-galactosyl epitopes in man. A trigger for autoimmune diseases? Lancet 2, 1989; 8651: 358-361
8. Jackson, S.: Immunoglobulin-antiimmunoglobulin interactions and immune complexes in IgA nephropathy. Am. J. Kidney Dis. 12, 1988; 429: 425-429
9. Jennette, J. C., Wieslander, J., Tuttle, R. et al.: Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schoenlein purpura: diagnostic value and pathologic implications. The glomerular disease collaborative network. Am. J. Kid. Dis. 18, 1991; 4: 466-471
10. Lai, K. N., Leung, J. C.: Pathogenic role of the IgA molecule in IgA nephropathy. Nephrology 7, 2002; Suppl., S86-S91
11. Litzman, J., Bartoňková, D., Pikulová, Z. et al.: Podtřidy IgG a autoprotilátky u dospělých pacientů se selektivnim deficitem IgA. Vniť. Lék. 46, 2000; 3: 170-173
12. Madaio, H. P.: Renal biopsy. Kidney Int. 38, 1990; 3: 529-543
13. Matousovic, K., Rossmann, P.: IgA glomerulopathy (Berger's disease). Vnitř. Lék. 83, 1983; 6: 588-597
14. Matoušovic, K., Rossmann, P.: Primary glomerulonephritis. Clinical and morphological aspects of diagnosis and prognosis. Academia: Praha, 1994, 190 s.
15. Matoušovic, K., Martinek, V., Špatenka, et al.: Význam biopsie ledviny v současné nefrologii. Prakt. Lék. 79, 1999; 4: 194-198
16. Mestecky, J., Hashim, O. H., Tomana, M.: Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1. Contrib. Nephrol. 111, 1995; 66-72
17. Mestecky, J., Novak, J., Julian, B. A. et al.: Pathogenic potential of galactose-deficient IgA1 in IgA nephropathy. Nephrology 7, 2002; Suppl., S92-S99
18. Monhart, V.: IgA nefropatie. Interní medicina pro praxi 10, 2001; 512-516
19. Novak, J., Tomana, M., Kilian, M. et al.: Heterogeneity of O-glycosylation in the hinge region of human IgA1. Molecular Immunol. 37, 2000; 7: 1047-1056
20. Novak, J., Julian, B. A., Tomana, M. et al.: Progress in molecular and genetic studies of IgA nephropathy. J. Clin. Immunol. 21, 2001; 5: 310-327
21. Odani, H., Hiki, Y., Takahashi, M. et al.: Direct evidence for decreased sialation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy bys mass spectrometry. Bioch. Biophys. Res. Comm. 271, 2000; 1: 268-274
22. Richards, N. T., Darby, S., Howie, A. J. et al.: Knowledge of renal histology alters patient management in over 40% of cases. Nephrol. Dial. Transpl. 9, 1994; 9: 1255-1259
23. Rudd, P. M., Elliott, T., Cresswoll P. et al.: Glycposylation and the immune system. Science 291, 2001; 5512: 2370-2376
24. Stockert, R. J., Kressner, M. S., Collins J. C. et al.: IgA interaction with the asialoglycoprotein receptor. Proc. Natl. Acad. Sci. USA 79, 1982; 20: 6229-6231
25. Tomana, M., Matoušovic, K., Julian, B. A. et al.: Galactose-deficient IgA1 in sera of IgA nephropathy is present in complexes with IgG. Kidney int. 52, 1997; 2: 509-516
26. Tomana, M., Novak, J., Julian, B. A. et al.: Circulating immune complexes in IgA nehropathy consist of IgA1 with galactose deficient hinge region and antiglycan antibodies. J. Clin. Invest. 104, 1999; 1: 73-81
27. Varki, A.: Biological role of oligosaccharides: All of the theories are correct. Glycobiology 3, 1993; 2: 97-130